Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model | Zendy

Ólanrewaju O. Okusanya | Zendy; Alan Forrest | Zendy; Sujata M. Bhavnani | Zendy; Prabhavathi Fernandes | Zendy; Paul G. Ambrose | Zendy; David R. Andes | Zendy

Open Access

Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model

Author(s) -

Ólanrewaju O. Okusanya,

Alan Forrest,

Sujata M. Bhavnani,

Prabhavathi Fernandes,

Paul G. Ambrose,

David R. Andes

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02606-18

Subject(s) - streptococcus pneumoniae , pharmacodynamics , pneumonia , antimicrobial , ketolide , bacterial pneumonia , medicine , pharmacokinetics , neutropenia , pharmacology , microbiology and biotechnology , antibiotics , biology , immunology , toxicity

Solithromycin (CEM-101) is a novel fluoroketolide antimicrobial agent with activity against typical and atypical pathogens associated with community-acquired bacterial pneumonia. Using a neutropenic murine lung infection model, the objectives of this study were to identify the pharmacokinetic/pharmacodynamic (PK/PD) index most closely associated with efficacy and the magnitude of such indices associated with solithromycin efficacy againstStreptococcus pneumoniae .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research